Nasdaq News

Like many industries during the COVID-19 pandemic, the automotive industry has been hit hard. Manufacturers such as Ford and General Motors temporarily idled plants, dealerships struggled with dwindling foot traffic and cautious consumers, and vehicle rental company Hertz filed

In trading on Wednesday, shares of Dana Inc (Symbol: DAN) crossed above their 200 day moving average of $13.89, changing hands as high as $14.38 per share. Dana Inc shares are currently trading up about 6.6% on the day. The chart below shows the one year performance of DAN s

In trading on Wednesday, shares of Thomson Reuters Corp (Symbol: TRI) crossed above their 200 day moving average of $70.32, changing hands as high as $70.96 per share. Thomson Reuters Corp shares are currently trading up about 0.5% on the day. The chart below shows the one y

In trading on Wednesday, shares of Owens Corning (Symbol: OC) crossed above their 200 day moving average of $56.01, changing hands as high as $56.28 per share. Owens Corning shares are currently trading up about 4.7% on the day. The chart below shows the one year performance

In trading on Wednesday, shares of KBR Inc (Symbol: KBR) crossed above their 200 day moving average of $25.34, changing hands as high as $26.36 per share. KBR Inc shares are currently trading up about 5.6% on the day. The chart below shows the one year performance of KBR sha

Merger and acquisition (M&A) activity has been put on pause in most industries, and banking is certainly no exception. However, Tom Michaud, president and CEO of Keefe, Bruyette & Woods (KBW), a bank research firm and investment bank, recently said on CNBC's The Exchan

The following are today's upgrades for Validea's Contrarian Investor model based on the published strategy of David Dreman. This contrarian strategy finds the most unpopular mid- and large-cap stocks in the market and looks for improving fundamentals.

The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.

The following are today's upgrades for Validea's Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundamentals and strong price performance.

SPECIAL ALERT: The June episode of the Zacks Ultimate Strategy Session will be available for viewing no later than Wednesday, June 10. Kevin Matras, Kevin Cook, Brian Bolan and Sheraz Mian will cover the investment landscape from several angles in this popular event. Don’t

As Americans have spent weeks staying put at home to slow the spread of COVID-19, the stock market has gone on a wild ride, first crashing and then rallying even as unemployment reached record highs. 

The stock market has taken investors on quite a roller-coaster ride in 2020. After reaching all-time highs in February, the S&P 500 and Dow Jones Industrial Average plunged by as much as 40% as the COVID-19 pandemic intensified. Since then, the major indexes have rebounded s

It is no secret that prescription drug prices in America are the highest among all developed nations. A variety of factors have contributed to the issue, such as a lack of universal healthcare coverage, the staggering cost of conducting clinical trials to get drugs to approval,

Blink and you would have missed Veeva Systems' (NYSE: VEEV) coronavirus slump. The stock is up 55% 2020 to date, driven by continued migration to its cloud-based software for pharmaceutical and biotech companies. The battle to develop treatments for infectious disease and other

Image source: The Motley Fool.

During the pandemic, one might think Dollar Tree (NASDAQ: DLTR) stock would have performed quite well. Its grocery business kept it "essential," and low price points make it affordable to shoppers from any income level.

These days, Regeneron (NASDAQ: REGN) seems to be the miracle stock that biotech investors are looking for. Sales of its biologic drug for ocular health, Eylea, and its anti-inflammatory drug, Dupixent, are soaring. Meanwhile, the company is also developing a promising antibody

Millions of seniors look to Social Security to help fund their retirements. In fact, those benefits are a major source of income for 64% of retirees today, according to the Society of Actuaries.

While companies that produce the newest tech innovations might seem more exciting to invest in than those that purvey burritos or toilet paper, investors' focus should be on growing their money, and growth can come from anywhere.